Citadel Advisors’s Aktis Oncology AKTS Stock Holding History
Bought
Maintained
Sold
Other funds holding AKTS
Citadel Advisors's AKTS Position: Q3 2026 in Review
Citadel Advisors increased its Aktis Oncology (AKTS) stake by 354% in Q3 2026, buying an estimated $2.2M and bringing the position to 115,857 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #6450.
Citadel Advisors first reported a position in AKTS in Q1 2026 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.
- Citadel Advisors held 115,857 shares of Aktis Oncology worth $2.26M as of Q3 2026.
- Citadel Advisors bought 90,320 Aktis Oncology shares in Q3 2026, an estimated $2.2M.
- Aktis Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6450 holding.
- Citadel Advisors first reported a position in Aktis Oncology in Q1 2026 and has held it in 3 quarters since.
- 124 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.